Founded in December 2013, Adjuvatis is specialized in the development, manufacturing and formulation of two innovative delivery systems, called i-Particles® and i-LipoP®.

i-Particles® were initially developed in 2003 by a joint research unit between the French National Center for Scientific Research (CNRS) and bioMérieux company, a global leader in in vitro diagnostics. Ten years of development raised promising interests in many healthcare fields and led to the creation of Adjuvatis. More recently, i-LipoP®, has emerged from the 2020 public health crisis, allowing vectorization of nucleic acids.

From R&D to production, Adjuvatis offers a wide variety of i-Particles® and i-LipoP®-based products and operates services for API formulation in the fields of vaccines, drug delivery and diagnostics. Adjuvatis also provides analytical services for customers’ formulations and colloidal technologies.